Chief Financial Officer Joseph Geraci reported, "Our fourth quarter 2025 results include a $196,100,000 non-cash unrealized and realized loss related to mark-to-market accounting adjustments on our ...
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2025 Earnings Call Transcript February 26, 2026 Nautilus Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.11, expectations were $-0.14 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results